Hims Launches GLP-1 Microdosing Treatments for Sale
Hims & Hers has announced the launch of GLP-1 microdosing treatments, focusing on their availability for individuals seeking alternatives to mainstream weight-loss options. This innovative offering positions them to compete directly with established drugs such as Novo Nordisk’s Wegovy, an important player in the weight-loss medication market.
Overview of GLP-1 Microdosing Treatments
Microdosing refers to administering smaller than standard doses of medication. This approach can potentially reduce side effects and lower costs. Hims is marketing these GLP-1 microdoses as a solution for overall metabolic health rather than strictly for weight loss.
Pricing and Availability
- The GLP-1 microdosing treatments will be priced at $1,200 for a six-month plan, payable upfront.
- Current offerings include compounded semaglutide, the active ingredient in Novo Nordisk’s Wegovy, with similar dosing.
Hims plans to expand its treatment options to cater to individuals with various metabolic health issues, going beyond just body mass index (BMI) considerations. Conditions like sleep apnea and high blood pressure will be included in the eligibility criteria for these treatments.
Market Context and Company Strategy
The announcement follows significant growth for Hims, particularly after it began selling alternatives to Wegovy during a national shortage. Although the supply chain issues have lessened, Hims continues to provide “personalized” versions of Wegovy, often in dose sizes that are not available from Novo Nordisk.
In June, a prior partnership between Hims and Novo to offer Wegovy at a lower cash-pay price ended sourly. Novo accused Hims of illegal compounding practices and misleading marketing, leading to speculation about potential legal action against Hims.
Regulatory Concerns
Recent developments include a warning letter from the FDA concerning Hims and other companies that sell GLP-1 medications. Microdoses, like other compounded treatments, remain unapproved and understudied according to the FDA.
Competitive Landscape and Business Diversification
Hims is not alone; competitors, such as Noom, also provide similar microdosing programs at comparable price points. As Hims continues to diversify its offerings, including testosterone treatments and menopause regimens, it faces challenges in maintaining steady revenue growth.
Hims CEO Andrew Dudum has openly discussed his usage of a GLP-1 microdose, linking personal experience to the company’s product offerings. Nevertheless, investor attention remains focused on the company’s upcoming earnings report for indicators of revenue health.
As the healthcare landscape continues to evolve, Hims will need to navigate regulatory scrutiny while leveraging its innovative approaches to treatment.
